Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia.

Trial Profile

Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs Sargramostim (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jan 2015 Status changed from active, no longer recruiting to discontinued, as reported by M.D. Anderson Cancer Center record.
    • 29 Sep 2014 Planned End Date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 30 Sep 2013 Planned end date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top